Endurant Capital Management’s Array Biopharma Inc ARRY Stock Holding History

Endurant Capital Management’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-16,447	Closed	-$401K	–	89
2019 Q1	$401K	Sell	16,447 -85,898	-84%	-$1.79M	0.16%	64
2018 Q4	$1.46M	Sell	102,345 -10,355	-9%	-$157K	0.77%	32
2018 Q3	$1.71M	Buy	112,700 +31,284	+38%	+$479K	0.76%	36
2018 Q2	$1.37M	Buy	81,416 +10,016	+14%	+$159K	0.59%	42
2018 Q1	$1.17M	Buy	71,400 +20,800	+41%	+$333K	0.44%	51
2017 Q4	$648K	Sell	50,600 -40,400	-44%	-$460K	0.2%	68
2017 Q3	$1.12M	Buy	91,000 +7,300	+9%	+$67.8K	0.34%	65
2017 Q2	$701K	Buy	+83,700	New	+$684K	0.2%	79
2017 Q1	–	Sell	-28,100	Closed	-$247K	–	101
2016 Q4	$247K	Buy	28,100 +18,100	+181%	+$133K	0.1%	65
2016 Q3	$68K	Buy	+10,000	New	+$38.7K	0.03%	96

Other funds holding ARRY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Endurant Capital Management's ARRY Position: Q2 2019 in Review

Endurant Capital Management sold out of Array Biopharma Inc (ARRY) in Q2 2019, closing a stake of 16,447 shares — an estimated $401K sold.

Endurant Capital Management first reported a position in ARRY in Q3 2016 and held it in 10 quarters. The position peaked at $1.71M in Q3 2018. 318 funds tracked by Wall St. Rank hold ARRY as of Q2 2019.

Endurant Capital Management reported no remaining Array Biopharma Inc position as of Q2 2019 after selling out during the quarter.
Endurant Capital Management sold 16,447 Array Biopharma Inc shares in Q2 2019, an estimated $401K.
Endurant Capital Management first reported a position in Array Biopharma Inc in Q3 2016 and held it in 10 quarters.
Endurant Capital Management's Array Biopharma Inc position peaked at $1.71M in Q3 2018.
318 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2019.

Based on Endurant Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.